Everest Organics Limited submitted exchange unaudited financials results for the quarter and nine months ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Everest Organics, an Active Pharmaceutical Ingredients (API) and intermediates maker, reported revenue from operations of Rs. 4,259 lakhs for Q3 FY26, up modestly from Rs. 4,205 lakhs a year ago, while nine-month revenue rose about 24% YoY to Rs. 14,741 lakhs from Rs. 11,854 lakhs. The company swung to a profit after tax of Rs. 35.6 lakhs in Q3 (vs Rs. 114 lakhs YoY) and Rs. 291.7 lakhs for nine months, compared to a loss of Rs. 420 lakhs in the prior year period. Total comprehensive income for nine months stood at Rs. 35.6 lakhs after a Rs. 256 lakh negative OCI hit. The statutory auditor, P.S.N. Ravishanker & Associates, issued a qualified limited review report flagging three issues: production beyond TSPCB-approved capacity without proper CFE/CFO consents (raising going concern concerns), Rs. 143 lakhs of supplier interest claims not provided for, and non-determination of additional employee benefit obligations under the new Labour Code.
The strong nine-month revenue growth and swing back to profit are positives for shareholders, but the auditor's qualifications — especially the explicit going concern reference and pending pollution board approvals — are material risks that could weigh on the stock and cap upside until regulatory clearances come through.